Milotay, Gusztav
Little, Martin https://orcid.org/0000-0003-2592-1570
Watson, Robert A.
Muldoon, Dylan
MacKay, Sophie
Kurioka, Ayako
Tong, Orion https://orcid.org/0000-0002-0659-5944
Taylor, Chelsea A.
Nassiri, Isar
Webb, Louisa M.
Akin-Adigun, Oluwafemi
Bremke, Julia https://orcid.org/0009-0002-2772-7675
Ye, Weiyu
Sun, Bo https://orcid.org/0000-0002-5507-6657
Sharma, Piyush Kumar
Cooper, Ros
Danielli, Sara
Santo, Flavia Matos
Verge de Los Aires, Alba
Niu, Guangyi
Cohen, Lea https://orcid.org/0000-0003-3971-648X
Ng, Esther
Gilchrist, James J. https://orcid.org/0000-0003-2045-6788
Chong, Amanda Y.
Mentzer, Alex https://orcid.org/0000-0002-4502-2209
Woodcock, Victoria https://orcid.org/0000-0001-7656-728X
Coupe, Nicholas
Payne, Miranda J.
Youdell, Michael
Middleton, Mark R. https://orcid.org/0000-0003-0167-1685
Klenerman, Paul
Fairfax, Benjamin P. https://orcid.org/0000-0001-7413-5002
Funding for this research was provided by:
Wellcome Trust (226535/Z/22/Z, 222426/Z/21/Z, 226535/Z/22/Z, BST00070, 226535/Z/22/Z, 226535/Z/22/Z, 226535/Z/22/Z, 226535/Z/22/Z, 201488/Z/16/Z, 201488/Z/16/Z, 201488/Z/16/Z, 201488/Z/16/Z, 222426/Z/21/Z, 226535/Z/22/Z, 226535/Z/22/Z)
Cancer Research UK (DRCNPG-Nov22/100005, DRCNPG-Nov22/100005)
DH | National Institute for Health Research (Oxford BRC, ACL)
Article History
Received: 23 December 2024
Accepted: 7 March 2025
First Online: 23 April 2025
Competing interests
: In the last 3 years, B.P.F. has performed consultancy for NICE Consultancy, Roche, Pathios, UCB and TCypher and has been given speaker fees by GSK, UCB and BMS, all outside the submitted work. M.R.M. reports grants from Roche, grants from Astrazeneca, grants from GSK, expenses from Novartis, grants and expenses from Immunocore, expenses from BMS, expenses from Pfizer, expenses from Merck/MSD, expenses from Regeneron, expenses from BiolineRx, expenses from Replimune and grants from GRAIL, all outside the submitted work. The other authors declare no competing interests.